Eli Lilly Hands China Commercial Rights for Verzenios to Innovent Biologics
Eli Lilly has moved exclusive mainland China commercialization rights for its breast cancer drug Verzenios to Innovent Biologics. Under the agreement, Innovent will market the drug across the mainland while Lilly remains responsible for manufacturing, supply and ongoing development. The deal comes as a locally approved generic and patent timing sha…